Nuclear reprogramming of somatic tissue enables derivation of induced pluripotent stem (iPS) cells from an autologous, non-embryonic origin. The purpose of this study was to establish efficient protocols for lineage specification of human iPS cells into functional glucose-responsive, insulin-producing progeny. We generated human iPS cells, which were then guided with recombinant growth factors that mimic the essential signaling for pancreatic development. Reprogrammed with four stemness factors, human fibroblasts were here converted into authentic iPS cells. Under feeder-free conditions, fate specification was initiated with activin A and Wnt3a that triggered engagement into definitive endoderm, followed by priming with fibroblast growth factor 10 (FGF10) and KAAD-cyclopamine. Addition of retinoic acid, boosted by the pancreatic endoderm inducer indolactam V (ILV), yielded pancreatic progenitors expressing pancreatic and duodenal homeobox 1 (PDX1), neurogenin 3 (NGN3) and neurogenic differentiation 1 (NEUROD1) markers. Further guidance, under insulin-like growth factor 1 (IGF-1), hepatocyte growth factor (HGF) and N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), was enhanced by glucagon-like peptide-1 (GLP-1) to generate islet-like cells that expressed pancreas-specific markers including insulin and glucagon. Derived progeny demonstrated sustained expression of PDX1, and functional responsiveness to glucose challenge secreting up to 230 pM of C-peptide. A pancreatogenic cocktail enriched with ILV/GLP-1 offers a proficient means to specify human iPS cells into glucose-responsive hormone-producing progeny, refining the development of a personalized platform for islet-like cell generation.
INTRODUCTION
As a result of their high self-renewing capacity and potential to generate cells of all organ systems in the body, embryonic stem (ES) cells have been considered as a natural source for cell replacement therapy. 1, 2 However, their use is dependent on embryonic tissue procurement and restricted by allogeneic mismatch, preventing application in clinical practice. The alternative bioengineered approach, based on nuclear reprogramming technology, enables generation of autologous pluripotent stem cells from a non-embryonic source through ectopic expression of multiple stem cell-related genes. [3] [4] [5] [6] Derived human induced pluripotent stem (iPS) cells, which recapitulate salient features of human ES cells, have in fact been differentiated into a wide variety of cell types. [7] [8] [9] [10] Type I diabetes (TID) is a chronic autoimmune disease that destroys pancreatic b-cells and induces an absolute insulin deficiency. Patients with TID depend on the administration of exogenous insulin for survival; however, fluctuations of blood glucose levels often lead to severe diabetes-related complications. Transplantation of whole pancreas or primary islets is a promising therapeutic option for TID. 11, 12 Yet, shortage of matched islet-replacement tissues has prevented the widespread use of this therapy. Alternative therapeutic approaches include transplantation of insulin-secreting cells generated from self-renewable cell sources. [13] [14] [15] In this regard, efficient differentiation of human iPS cells would offer the potential for generation of replenishable, islet-like cells, which could be used to restore euglycemia and insulin independence.
Directed differentiation of pluripotent stem cells into pancreatic lineage requires understanding of pathways controlling pancreas development. The critical steps in differentiation are the generation of cells comprising the definitive endoderm, and ultimately generation of pancreatic endoderm. Based on developmental biology insight, 16, 17 strategies have been recently developed to generate endoderm and pancreatic b-like cells from ES cell sources. Activin A and low serum concentrations have been shown to differentiate mouse and human ES cells into definitive endoderm, respectively. 18, 19 This process can be enhanced by addition of Wnts. 20 Retinoic acid (RA) signals are required for development of Pdx1-positive cells from the endoderm in zebrafish and mouse models 21, 22 and, furthermore, RA has been reported to promote generation of Pdx1-positive cells from mouse and human stem cells in vitro. 23, 24 Recently, the small-molecule indolactam V (ILV), in combination with fibroblast growth factor 10 (FGF10), has also been reported to generate PDX1 (pancreatic and duodenal homeobox 1)-positive pancreatic endoderm cells from human ES cells. 25 Based on incremental advances in the decoding of signaling networks in pancreatic development, stepwise differentiation protocols have been established for the generation of pancreatic b-like cells from ES cells. 20, [26] [27] [28] Although up to 12% of insulin-expressing cells have been derived from a human ES cell pool, responsiveness to glucose stimulation has remained poor. 20 iPS cells have also been most recently differentiated into C-peptidepositive cells through stimulation with a combination of activin A and sodium butyrate with additional growth factors. 29 Moreover, iPS cells from two diabetic patients were successfully differentiated into pancreatic b-like cells in vitro. 30 However, iPS-derived islet-like cells have been reported to secrete low levels of C-peptide in response to glucose stimulation, and variation in differentiation propensities were observed among iPS cell clones. 29 Thus, despite remarkable progress, it still remains challenging to achieve efficient differentiation of human pluripotent stem cells into functional insulin-producing cells, a prerequisite for the establishment of robust, functional platforms for bioengineered islet generation.
In this study, we generated human iPS cells under feeder-free conditions, which were then guided with recombinant growth factors that mimic the essential signaling for pancreatic development. Inclusion of ILV achieved efficient generation of PDX1-, neurogenin 3 (NGN3)-and neurogenic differentiation factor 1 (NEUROD1)expressing pancreatic endoderm through the FOXA2 (Forkhead box A2)-and SOX17 (SRY (sex determining region Y)-box containing gene 17)-positive definitive endoderm. Further guided differentiation with glucagon-like peptide-1 (GLP-1), which is known to increase b-cell mass and enhance insulin gene expression, 31 resulted in generation of functional islet-like cells. Importantly, iPS-derived islet-like cells sustained PDX1 expression, and secreted up to 230 pM of C-peptide. Our data therefore demonstrate that inclusion of ILV and GLP-1 in pancreatogenic cocktail regimens facilitates generation of glucose-responsive islet-like cells from a human iPS cell source.
RESULTS

Reprogramming of human fibroblasts with stemness factors
Human cardiac fibroblasts (HCFs) and BJ fibroblasts were infected with lentiviral vectors encoding OCT4, SOX2, KLF4 and c-MYC, and transduced cells re-seeded on mitomycin C-inactivated SNL feeder cells or replated on matrigel-coated plates to ensure feeder-free culture. On SNL feeder cells, reprogrammed colonies, characterized by distinct morphology of sharp-edged, flat and tightly packed structures, were visible 2 weeks after viral vector transduction ( Figure 1a ). Under feeder-free conditions, similar colonies were observed as early as day 6 after viral vector infection ( Figure 1b ) with clusters of 30-50 cells expressing alkaline phosphatase (Supplementary Figure S1 ). The number of expandable colonies formed on feeders or on non-feeder plates were 5-20 clones per 10 5 transduced cells. Identified colonies were picked at 3-6 weeks to allow sufficient growth after viral transduction.
Expression of pluripotency markers in derived iPS cell clones Over 3-9 months or 30-90 passages, putative iPS cell clones cultured under feeder-free and serum-free conditions exhibited a distinctive morphology similar to that of human ES cells over long-term culture (Figure 1c ). Tested clones expressed high levels of alkaline phosphatase ( Figure 1d ). Immunocytochemistry revealed expression of SSEA-4, TRA-1-60, TRA-1-81, OCT4, SOX2, KLF4 and NANOG in multiple clones (Figures 2a and b ). These clones were negative for SSEA-1 expression. Reverse transcriptase-PCR of total cellular RNA further demonstrated induction of endogenous pluripotency-associated genes, including OCT4, SOX2, GDF3, telomerase (TERT), KLF4, c-MYC and NANOG (Figure 2c , Supplementary Table 1 ). No notable difference was observed between clones isolated from BJ fibroblasts and HCFs, or with clones isolated with SNL feeder cells. Morphology and expression of stem cell genes indicate establishment of human iPS cell clones from fibroblasts, and maintenance in an undifferentiated state under feeder-free conditions.
Pluripotency validated through three germ layer differentiation
Human iPS cell clones were assayed, through embryoid body formation, for the ability to spontaneously differentiate in vitro into cells of the three embryonic germ layers. All iPS cell clones assayed formed embryoid bodies ( Figure 3a ). After variable times in suspension, embryoid bodies were transferred to adherent conditions and further cultured. Immunostaining for lineage-specific markers confirmed that human iPS cells differentiated into ectoderm (b-III tubulin, Figure 3a ), endoderm (FOXA2, Figure 3a ) and mesoderm (CD31, Figure 3a ) lineages. Moreover, in vivo human iPS cells formed teratomas after injection into nude mice. These subcutaneous tumors enlarged up to 1 cm in diameter within 3 months post-injection ( Figure 3b ). Histology revealed diverse cell types, including glandular epithelium (ectoderm, Figure 3c ), adipose (endoderm, Figure 3c ) and muscular (mesoderm, Figure 3c ) tissues. Thus, human iPS cells generated from BJ fibroblasts and HCFs exhibit hallmark properties of pluripotent stem cells.
Differentiation of human iPS cells into pancreatic endoderm
Normal differentiation of a pluripotent precursor into lineage-specified pancreatic endodermal tissue encompasses multiple steps. Here, verified iPS cells were treated first with activin A and Wnt3a for generation of definitive endoderm cells, and then with FGF10 and KAAD-cyclopamine (CYC) for derivation of gut tube endoderm ( Figure 4a ). Derived cells were further treated with FGF10, RA and CYC in the absence or presence of ILV for generation of pancreatic endoderm, followed by culture in HGF, insulin-like growth factor (IGF) and DAPT in the absence or presence of GLP-1 for generation of pancreatic hormone-expressing cells (Figure 4a ). In this way, human iPS cell clones were induced to form definitive endoderm by treatment with activin A and Wnt3a initially for 1 day followed by culture in activin A and 2% fetal bovine serum (FBS) for 2 additional days. Immunostaining of treated cells revealed efficient SOX17 and FOXA2 induction, the markers of definitive endoderm ( Figure 4b ). Similar results were observed with clones generated from human cardiac fibroblasts or foreskin (Supplementary Figure S2 ). Flow cytometry demonstrated that 92, 72 and 84% cells were positive for SOX17 in three distinct clones, respectively (Figure 4c ; Supplementary Figure  S2 ). Next, we evaluated the efficiency of definitive endoderm transformation into pancreatic endoderm. Our initial attempts to generate pancreatic endoderm by stimulating definitive endoderm cells with FGF10 and CYC for two days, followed by FGF10, RA and CYC stimulation, resulted in cells with low levels of PDX1 expression (data not shown). We therefore included ILV, which was recently demonstrated to efficiently induce pancreatic endoderm from definitive endoderm. 25, 32 In our protocol, treatment of iPS-derived definitive endoderm cells with FGF10, RA and CYC in the presence of ILV resulted in cells expressing PDX1, NEUROD1 and NGN3, the markers of pancreatic endoderm (Figure 4d ). Similar results were observed for iPS cells derived from human cardiac fibroblasts or foreskin (Supplementary Figure S3 ). These results indicate successful induction of pancreatic endoderm from iPS-derived definitive endoderm.
Induction of stage-specific pancreatic genes through guided differentiation
To determine the expression of endocrine-specific transcription factors and pancreas-specific genes throughout differentiation, we analyzed the gene expression pattern at each stage of differentiation. Reverse transcriptase-PCR detected high levels of FOXA2 expression after 3 days of differentiation, confirming induction of definitive endoderm cells ( Figure 5a ). The expression of the endocrine progenitor-specific gene, NGN3, was observed from day 3 of differentiation, and the expression persisted throughout the differentiation process ( Figure 5a ). Expression of the islet-specific gene, ISL-1, was also found from day 3, with expression levels increasing at later time points ( Figure 5a ). Moreover, PDX1 and NEUROD1 transcripts, which were found only after treatment with FGF10, RA CYC and ILV, further confirmed the generation of iPS-derived pancreatic endoderm cells upon differentiation (Figure 5a ). To evaluate whether human iPSderived pancreatic endoderm cells are capable of generating functional pancreatic islet-like cells, we proceeded with an additional step of differentiation. We initially treated the iPS-derived pancreatic endoderm with HGF, IGF, exendin-4 and DAPT; however, we failed to detect C-peptide secretion from resulting cells (data not shown). We therefore included GLP-1, which is known to increase b-cell mass, 31 
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including insulin, glucagon (GCG) and somatostatin (SST), and islet cell-specific marker genes PDX1, NKX6.1, ISL1 and NEUROD1 and glucose transporter 2 (GLUT2) ( Figure 5a ). Conversely, to determine whether pluripotency genes were silenced during differentiation, we performed reverse transcriptase-PCR analysis for c-MYC, GDF3, hTERT, NANOG, SOX2 and KLF4. We found that c-MYC, GDF3, hTERT and NANOG gene expression levels gradually decreased during differentiation, whereas these gene transcripts were absent in the human pancreas (Figure 5b ). SOX2 and KLF4 gene expression remained throughout iPS cell differentiation, in line with expression of these two genes in the human pancreas ( Figure 5b ). The targeted downregulation of pluripotency genes along with sequential 
Differentiation of iPS cells into insulin-secreting islet-like progeny
During treatment with RA, FGF10, CYC and ILV, iPS-derived pancreatic endoderm cells started to form spheroid-like cell clusters, which reached maximum size and number following further maturation with HGF, IGF, DAPT and GLP-1 (Figure 5c ). The threedimensional morphology resembled pancreatic islet-like clusters, 14 and selected clones yielded clusters ( Figure 5c ) strongly positive for C-peptide expression ( Figure 5d ). Importantly, even iPS-derived isletlike cells that did not organize into typical clusters also expressed insulin, C-peptide and glucagon ( Figure 5e ). The presence of insulin/ C-peptide coexpressing cells (Figure 6ai ) confirmed the potential for de novo insulin synthesis and excluded the possible artifact of insulin uptake from the media. Also, we did not observe insulin-glucagon double-positive cells, indicating that the expression pattern of iPSderived hormone-expressing islet-like cells is consistent with normal pancreatic b-cell development. Although few insulin and somatostatin double-positive cells were found (Figure 6aii ), characteristic of immature islet cells, our results indicate successful differentiation of iPS cells into hormone-expressing islet-like cells. Indeed, similar to pancreatic b-cells that coexpress insulin and PDX1, the majority of the insulinexpressing cells showed nuclear-localized PDX1 signals ( Figure 6aiii ). When we quantified by flow cytometry the insulin-positive population, 1.3, 0.7 and 0.8% of distinct clone-derived islet-like cells were insulin positive (Figure 6b ; Supplementary Figure S4 ).
Functional response of iPS-derived islet-like clusters
Finally, we analyzed C-peptide secretion from iPS-derived islet-like clusters in response to glucose challenge, the critical physiological function of pancreatic b-cells. To determine whether islet-like cells are capable of C-peptide secretion in response to glucose induction, cells were exposed to increasing concentrations of glucose, and secreted C-peptide was measured by enzyme-linked immunosorbent assay. At extracellular glucose levels of 2.5 mM, which mimics a fasting condition, there was only marginal detection of the C-peptide signal (Figure 6c ). Raising glucose levels to 10 mM induced marked secretion of C-peptide by iPS-derived islet-like cells (Figure 6c ). Further raising glucose levels to the supraphysiological 27.7 mM range triggered an additional bolus of secreted C-peptide, reaching cumulatively the range of 72.0-236.1 pM (HCF#1, three independent experiments, Figure 6c ) or 12.1-50.9 pM (BJ#1). iPS-derived isletlike cells differentiated without ILV or GLP-1 failed to secrete C-peptide in response to glucose challenge (Figure 6d ). Although clonal variation in responsiveness was observed, iPS-derived islet-like clusters were typically capable of secreting C-peptide in response to glucose stimulation.
DISCUSSION
Islet cell transplantation is increasingly considered as a new-generation therapy for insulin-dependent diabetes. It is however limited by the availability of donor islets. Differentiation of human iPS cells into islet-like progeny would offer an alternative approach, ensuring an unlimited supply for islet-like cells. In this study, under feeder-free conditions, human iPS cell clones were successfully guided by a pancreatogenic cocktail-enriched with ILV/GLP-1-into islet-like cells that expressed pancreas-specific transcription factors and islet-specific hormones. Importantly, derived islet-like cells secreted C-peptide in response to glucose stimulation. The present study therefore establishes an iPS-based feeder-free protocol for derivation of functional hormone-producing progeny, expanding the armamentarium for islet-like cell generation. 
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Indeed, non-human feeder cells express undefined factors, which potentially compromise stem cell differentiation. Moreover, feeder cells have been reported to constitutively produce infectious endogenous retroviruses, often preventing immediate clinical application. To circumvent this limitation, we here generated feeder-free conditions using Matrigel-coated plates and an optimized serumfree medium, supplementing HEScGRO with 25% of mTeSR1. This previously untested approach achieved feeder-free/serum-free conditions, nurturing iPS cell expansion and maintaining the undifferentiated state in the long term. In this way, we were able to sustain multiple iPS cell clones in feeder/serum-free milieu for 41 year without loosing salient structural and genetic traits of pluripotency.
It is established that the initial step to achieve successful generation of islet-like cells from a pluripotent cell source requires differentiation into definitive endoderm. 32, 33 Stimulation of mouse or human ES cells with activin A, Nodal and/or Wnts leads to endoderm induction, 18, 20, 34 and was here implemented with human iPS cells. Specifically, we generated definitive endoderm cells by stimulating feeder-free human iPS cells with activin A and Wnt3a in the presence of low serum. Induction of definitive endoderm was particularly efficient, such that 70-90% of derived cells expressed the definitive endoderm marker SOX17. Similar results were observed across distinct iPS cell clones, derived from foreskin or cardiac fibroblasts, demonstrating that the applied approach offers a robust means for definitive endoderm induction.
Further lineage specification requires conversion of definitive endoderm into pancreatic endoderm. 35 A recent study has identified a small-molecule ILV, a protein kinase C activator, which strongly directs human ES cell-derived definitive endoderm into pancreatic endoderm. 25 Pancreatic endoderm induction by ILV alone has been shown to generate approximately 53% PDX1-positive cells, in contrast to 25% PDX1-positive cells achievable with standard inductors, FGF10, RA and CYC. 32 In this study, using human iPS-derived definitive endoderm, we demonstrated robust induction of pancreatic endoderm markers, PDX1, NGN3 and NEUROD1, only after inclusion of ILV to the FGF10, RA and CYC cocktail, underscoring the feasibility of generating pancreatic endoderm cells from human iPS cells through ILV-mediated guidance. It has been proposed that ILV may share an RA-dependent signaling pathway, 25 allowing ultimately to streamline the process of efficient pancreatic endoderm derivation. 
Human ES cells after guided differentiation to pancreatic hormoneexpressing cells generate up to 12% of insulin and synaptophysinexpressing cells. 20 However, these cells show minimal glucose-responsive C-peptide secretion and do not maintain expression of key b-cell markers, NKX6.1 and PDX1. 20 Foreskin-derived iPS cells or iPS cells from patients with TID were also recently differentiated into islet-like clusters in vitro; 29, 30 yet, generation of glucose-responsive insulinproducing cells from human iPS cells remains inefficient. GLP-1 was shown to convert intestinal epithelial cells into functional insulinproducing cells, 36 and could promote differentiation of mouse bone marrow 13 or human embryonic 37 stem cells into insulin-producing cells. Inclusion of GLP-1 in our differentiation cocktail enhanced the generation of insulin-producing cells from iPS-derived pancreatic endoderm cells. Derived islet-like cells expressed transcripts of PDX1, NKX6.1, NEUROD1, ISL-1 and GLUT2, the recognized b-cell-specific markers. Coexpression of insulin and PDX1, a characteristic of pancreatic b-cells, 38 was evident in iPS-derived insulinproducing cells by immunofluorescence. In contrast to previous reports that demonstrated limited PDX1 expression in ES cellderived insulin-producing cells, 20 we found prevalent insulin/ PDX1-double positive cells after differentiation. Moreover, these islet-like cells secreted C-peptide in response to glucose stimulation. These observations indicate that the ILV/GLP-1-containing pancreatogenic cocktail offers proficient means to specify human iPS cells into functional b-like cells.
Replacement of exendin-4 (120 nM) with GLP-1 (55 nM) in the final differentiation step notably improved the differentiation of iPSderived pancreatic endoderm into glucose-responsive, insulin-producing cells. Exendin-4, a 39-amino acid peptide secreted by the salivary gland of a venomous lizard, is a GLP-1 analog that binds and activates the GLP-1 receptor (GLP-1R). Intriguingly, exendin-4 and GLP-1 bind GLP-1R with similar affinity 39 but in different modes: exendin-4 relies largely on the N-domain for interaction, whereas GLP-1 utilizes the core domain for GLP-1R binding. 40 We speculate that iPS-derived endoderm cells express GLP-1R with differential post-translational modification, affecting the binding of GLP-1R with exendin-4, but not GLP-1. Alternatively, binding of GLP-1, but not exendin-4, to GLP-1R on iPS-derived endoderm cells may facilitate activation of a critical intracellular signaling pathway necessary for successful endoderm differentiation into glucose-responsive islet-like cells.
It is noteworthy that human iPS cell clones here demonstrated no notable differences in morphology, pluripotency marker expression and/or ability to differentiate into cells of the three germ layers. Although iPS cell clones were efficiently differentiated into definitive endoderm, they exhibited varying propensity to generate glucoseresponsive insulin-producing cells. Moreover, we noted that high levels of C-peptide remained in glucose-stimulated cells (data not shown), suggesting an immature insulin secreting system in iPSderived islet-like cells. In fact, it was notable that although certain clones displayed vigorous response to glucose with marked secretion stem cells, which could be because of varying degrees of reprogramming, different copy numbers of integrated pluripotency genes or different levels of pluripotency gene silencing/reactivation in individual clones. 29, 30, 41 Further analysis using multiple iPS cell clones and improved islet differentiation efficiency will be necessary to establish the mechanisms underlying unique functional property of derived lineage-specified cell progeny in vitro and in vivo.
Retroviral or lentiviral vector integration has risks associated with insertional mutagenesis. Use of oncogenic c-MYC during reprogramming is also problematic for clinical application of the resulting iPS cells, as sustained c-MYC expression can increase the risk of tumor formation in iPS-derived cells in vivo. Indeed, use of c-Myc has been associated with increased tumorigenicity in chimeric mice established with iPS cells. 42 Additionally, reactivation or sustained expression of pluripotency genes in iPS-derived islet-like cells could result in spontaneous reprogramming of iPS cell progeny, leading to the potential risk of teratoma formation upon transplantation. Indeed, residual expression of pluripotency-associated genes, such as c-MYC, NANOG, hTERT and GDF3, was evident in differentiating iPS cells (Figure 5b ), which is likely because of sustained vector transgene expression. Determining the levels of vector-derived and endogenous pluripotency gene expression in the different clones before and after differentiation will be necessary to understand the influence of integrating vectors on the diversity in differentiation propensities among iPS cell clones. In order to increase the safety of iPS-based cell therapy, it will be critical to generate iPS cells without integrating vectors and continuous c-MYC expression. Derivation of iPS cells with transient expression from non-integrating vectors [43] [44] [45] will solve both problems, as the resulting iPS cells carry no genomic modifications. To further minimize the risk of teratoma formation, it will be necessary to develop further strategies, such as sorting out fully differentiated cell populations by flow cytometry, eliminating residual pluripotent cells by a suicide gene vector or encapsulating the iPS-derived cells before transplantation.
In summary, we demonstrate that under feeder-free conditions, an ILV/GLP-1-enriched pancreatogenic cocktail allows derivation of glucose-responsive, insulin-producing cells from human iPS cells, providing a platform for islet-like cell generation. Autologous iPS cell derivation and iPS cell differentiation into insulin-producing cells would allow modeling of patient-specific disease pathogenesis, and ultimately lead to personalized approaches for TID cell therapy with iPS-derived islet-like cells.
MATERIALS AND METHODS
Plasmid construction and lentiviral vector production
Stemness factor-expressing lentiviral pSIN-CSGWdlNotI-derived transfer vectors were generated as described. 46 In brief, the packaging plasmid pEX-QV was engineered with H87Q mutation in the HIV-1 capsid region for increased transduction efficiency of purified infectious supernatants. 47 HIV vectors were produced by transient transfection of 293T cells and titrated by immunostaining. 47 Vectors expressed pluripotency factors from a SFFV (spleen focusforming virus) promoter. 47 
Generation and culture of human iPS cells on SNL feeder cells
Human neonatal foreskin fibroblasts (BJ1) (American Type Culture Collection (ATCC), Manassas, VA, USA; no. CRL-2522) and primary HCFs (ScienCell Research Laboratories, Carlsbad, CA, USA; no. 6300) were seeded 1 day before infection in wells of six-well plates with Dulbecco's modied Eagle's medium (DMEM) containing 10% FBS, penicillin (100 U ml -1 ) and streptomycin (100 mg ml -1 ) (complete DMEM). Fibroblasts were infected with lentiviral vectors expressing OCT4, SOX2, KLF4 and c-MYC at a multiplicity of infection of B5 each. After 12 h of viral infection, cells were fed with fresh complete DMEM. Vector-transduced cells were replated 4 days after infection at 5Â10 4 cells per 100 mm dish on mitomycin-C treated SNL feeder cells in complete DMEM. Next day, the medium was replaced with the serum-free HEScGRO medium (Millipore, Billerica, MA, USA; no. SCM020) supplemented with basic FGF (20 ng ml -1 ; PeproTech Inc., Rocky Hill, NJ, USA). Cells were fed with fresh HEScGRO medium every 2 days. Putative iPS cell colonies, which began to appear 3 to 4 weeks after vector transduction, were picked based on size and human ES cell-like colony morphology, and expanded through dissociation with the cell dissociation buffer (Invitrogen Corporation, Carlsbad, CA, USA; no. 13151014). BJ1-derived iPS cell clones, BJ#SA and BJ#SD, were generated on SNL feeder cells. Established iPS cell clones were maintained in feeder-free condition.
Feeder-free iPS cell generation and culture
For feeder-free iPS cell generation and maintenance on Matrigel (BD Biosciences, San Jose, CA, USA; no. 354277)-coated plates, we compared various commercially available stem cell media or their combinations. Optimal results were obtained when iPS cells were maintained in a feeder-free medium, which contained HEScGRO with 25% of mTeSR1 medium (STEMCELL Technologies Inc., Vancouver, BC, Canada; no. 05850) and 20 ng ml -1 of basic FGF (iPS cell medium). In order to generate feeder-free iPS cell clones from BJ fibroblasts and HCFs, cells were transduced with pluripotency factor-expressing lentiviral vectors, 4 days after infection; cells were re-plated at a density of 5Â10 5 cells on a Matrigel-coated 100 mm dish. Medium was replaced with fresh iPS cell medium every 2 days. Putative iPS cell colonies were observed 1 to 2 weeks after vector transduction. iPS cell clones were picked based on morphology and size. iPS cell clones were expanded with cell dissociation buffer and passaged at a 1:2-1:8 split ratio every 3-7 days depending on cell density. BJ#1, HCF#1 and HCF#6 iPS cell clones were generated and maintained under feeder-free conditions.
Immunostaining and alkaline phosphatase staining
For immunostaining, iPS cells were fixed for 20 min at room temperature in 4% paraformaldehyde in phosphate-buffered saline, washed in PBS and blocked for 30 min with 5% FBS in PBS with 0.1% Tween-20 (Sigma-Aldrich, St Louis, MO, USA). Cells were stained with primary antibodies overnight at 4 1C, rinsed by PBS and incubated with secondary antibodies for 1 h at room temperature. 48 Cells at different stages of differentiation were fixed and stained with primary and secondary antibodies. Primary and secondary antibodies used for characterization of iPS and derived cells were: SSEA-1, SSEA-4, 
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TRA-1-60, TRA-1-81 (Millipore; no. SCR001), OCT4 (Cell Signaling Technology, Inc., Danvers, MA, USA; no. 2750), SOX2 (Cell Signaling Technology; no. 2748), KLF4 (Abcam, Cambridge, MA, USA; no. ab26648), NANOG (Abcam; no. ab21624), mouse anti-SOX17 (R&D Systems Inc., Minneapolis, MN, USA; no. MAB1924), rabbit anti-HNF3 b/FOXA2 (Millipore; no. 07-633), rabbit anti-PDX1 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA; no. sc-25403), rabbit anti-NGN3 (Millipore; no. AB5684), rabbit anti-NEUROD1 (Abcam; no. 16508), mouse anti-insulin (Sigma; no. I2018), rabbit anti-Cpeptide (Cell Signaling Technology; no. 4593), rabbit anti-insulin (Cell Signaling Technology; no. 4590), mouse anti-proinsulin C-peptide (Millipore; no. CBL94), mouse anti-glucagon (Abcam; no. ab10988), MafA (Santa Cruz Biotechnology; no. sc-66958), and rabbit anti-somatostatin (Dako North America, Inc., Carpinteria, CA, USA; no. A0566). Texas Red-conjugated donkey-anti-rabbit IgG (Jackson Laboratories; no. 711-075-152), Texas Redconjugated donkey-anti-mouse IgG (Jackson Laboratories; no. 715-075-151), fluorescein isothiocyanate (FITC)-conjugated donkey-anti-rabbit IgG (Jackson Laboratories; no. 711-095-152) and FITC-conjugated donkey-anti-mouse IgG (Jackson Laboratories; no. 715-095-151) were used as secondary antibodies. For counterstaining, 4,6-diamidino-2-phenylindole (DAPI) was used. Stained cells were analyzed using confocal laser-scanning microscopy (Carl Zeiss, Thornwood, New York, USA; LSM 510 confocal scanning laser system). Alkaline phosphatase staining was performed with an Alkaline Phosphatase Detection Kit (Millipore) as described. 48 
Spontaneous differentiation
For spontaneous differentiation, iPS cell clones were dissociated using collagenase IV and plated on low adhesion plates in basal HEScGRO medium (SCM 021) without basic FGF. Embryoid bodies were cultured as suspension for 7-14 days and were adherent in knockout DMEM with 20% FBS for an additional 7-14 days. For immunofluorescence analysis, cells were fixed and stained. 48 Primary antibodies were FOXA2 for endoderm, b-III tubulin (Abcam; no. 41489) for ectoderm and CD31 (Santa Cruz Biotechnology; no. SC1506) for mesoderm, whereas Texas Red-conjugated donkey-anti-rabbit IgG (Jackson Laboratories; no. 711-075-152) and FITC-conjugated donkeyanti-chicken IgG (Jackson Laboratories; no. 703-095-155) were used as secondary antibodies.
Teratoma formation and analysis
Teratoma formation assay was performed using the protocol approved by the institutional animal care and use committee. iPS cells were injected subcutaneously into the flank skin of 2 to 3 months old athymic nude mice at 500 000 cells per 50 ml medium. Tumor growth was observed 4-6 weeks after injection. Tumors were processed by rapid freezing, cut as cryosections and stained with hematoxylin and eosin dyes. 47 In vitro differentiation of human iPS cells to insulin-secreting islet-like clusters
